focus -WSS

focus

author：explore 2025-09-29 18:59:42 - browse：4

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Novel spinal cord stimulator treats paralysis without surgery

focus

WSS

Bird flu researchers hone in on Finland’s mink farms

Judge sides with young activists in first

Class action alleges UnitedHealth concealed DOJ probe

Lawmakers grill UnitedHealth CEO on Change cyberattack

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Has Bernie Sanders reached the limit of his pharma bullying effort?

Wikipedia

focus

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

BMS, looking to build heart drug business, turns to AI for diagnosis

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Black vets could get higher VA benefits if race not used in lung test

In age of alternative facts, a scholarly course on calling out crap

Brain MRIs reveal impact of 'toxic stress' on Black children

Peter Hotez and the public health issue of online harassment

Lawmakers grill UnitedHealth CEO on Change cyberattack

How to save PrEP access — and even expand it

Patients, digital health players weigh in on FTC's data privacy plan

entertainment

Chemotherapy before breast cancer surgery might fuel metastasis

Maui wildfire now ranks as the fifth

Crowdfunding for medical bills sidesteps core problem, author says

BMS, looking to build heart drug business, turns to AI for diagnosis

Novel spinal cord stimulator treats paralysis without surgery

Crowdfunding for medical bills sidesteps core problem, author says

leisure time

focus

leisure time

knowledge